Intermediate- and high-risk cases (Sokal’s relative risk ≥ 0.8). Overall survival (A) and time to progression to accelerated or blastic phase (B). P values are .006 and .002. Notice that although IFN- patients fared significantly better than chemotherapy patients, more than 80% of IFN- patients progressed and died within 10 years as well.